CN105169004A - Medicine for treating bovine mastitis and preparation method, detection method and application of medicine - Google Patents
Medicine for treating bovine mastitis and preparation method, detection method and application of medicine Download PDFInfo
- Publication number
- CN105169004A CN105169004A CN201510538198.3A CN201510538198A CN105169004A CN 105169004 A CN105169004 A CN 105169004A CN 201510538198 A CN201510538198 A CN 201510538198A CN 105169004 A CN105169004 A CN 105169004A
- Authority
- CN
- China
- Prior art keywords
- medicine
- weight portion
- methanol
- solution
- hour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of traditional Chinese medicine, in particular to a medicine for treating bovine mastitis and a preparation method, a detection method and application of the medicine. The medicine is prepared from, by weight, 1-2 parts of vitis coignetiae and 1-2 parts of panicum repens. The medicine can be prepared into tablets, pills, powder, hard capsules, soft capsules and granules. The preparation method includes drying the vitis coignetiae and the panicum repens, soaking in 11 times the amount of water for 1 hour for the first time, decocting for 1 hour, adding 4 times the amount of water to decoct for 1 hour for the second time, blending two times of decoction, filtering, concentrating filtrate, drying, grinding into fine powder, sieving and mixing uniformly to obtain the powder. The medicine quality detection method includes that chromatographic condition: HypersilDs chromatographic column; mobile phase: methanol-0.15% phosphoric acid solution in a ratio of 30:70; detection wavelength: 200nm; column temperature: 20 DEG C; flow velocity: 1.0mL per min; sample size: 10 microliters. The medicine is reasonable in composition and remarkable in treatment effect.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to active medicine of a kind of Herba panici repentics and purple Pueraria lobota and preparation method thereof.
Background technology
Mammitis of cow, also known as bovine mastitis (bovinemastitis), is that cow mammary gland stimulates by physics, chemistry, microorganism the disease causing a kind of complexity of the symptoms such as mammary gland tissue local microcirculation obstacle, mammary gland alveolus generation pathological changes, immune dysfunction.Microorganism is the Etiological of mammitis of cow, and having found at present about has 150 multiple pathogens to cause mammitis of cow, and common bacteria, based on staphylococcus, streptococcus, escherichia coli, bacillus pyogenes, accounts for Isolated from Bovine Mastitis more than 90%.
According to dairy association of world statistics, whole world mammitis of cow incidence rate is about 50%.External mammitis of cow sickness rate is 25% ~ 60%, and China is 20% ~ 70%, and part cattle farm sickness rate is higher.After milch cow generation mastitis, body starts defense system and to cause in milk the somatic cells such as leukocyte to increase, and milk yield declines, and milk Quality Down, severe patient also may cause cow oestrus to reduce.Research report, the sick milch cow of average every hair loses every year and surpasses 100 dollars, and the loss that entire United States causes because of mammitis of cow is every year more than 2,000,000,000 dollars.The economic loss that the whole world causes because of mastitis is every year up to 35,000,000,000 dollars.
Since China is studied mammitis of cow from the eighties in 20th century, antibiotic is the choice drug for the treatment of mastitis always, wherein the antibiotic such as penicillin, streptomycin, gentamycin, cloxacillin sodium, ceftiofur sodium and chemical drugs are treated bacillary mammitis of cow clinically and are achieved very significant effect, and treatment rate is up to 90%.But the long-term a large amount of appearance using antibiotic to result in fastbacteria, superbacteria, the residual metabolite of all kinds of chemosynthesis medicine serious threat human health.Current, Safety of Food Quality causes the attention of society gradually, and begin one's study non-harmful, noresidue, the quick-acting medicine of novel green of research worker comes substitute antibiotics and chemical drugs treatment mammitis of cow.Nuisanceless, noresidue, become current study hotspot without the Chinese medicine of off-drug period.
Summary of the invention
The object of the invention is for the deficiencies in the prior art, the medicine of the treatment mammitis of cow providing a kind of reasonable recipe, therapeutic effect good.
Another object of the present invention is to provide the preparation method of this medicine.
Present invention also offers the quality determining method of this medicine.
Present invention also offers the pharmaceutical applications of this medicine.
Medicine of the present invention meticulously develops for many years through inventor, is mainly used in treating mammitis of cow.Medicine of the present invention can heat-clearing and toxic substances removing, promoting blood circulation to remove blood stasis, blood circulation of breast can be promoted again to dredge smooth, is conducive to scorching swollen absorption and dissipates, promote galactopoiesis, have good therapeutic effect to mammitis of cow.
As follows at the Ji Yuan of medicine Raw medicine of the present invention:
Purple Pueraria lobota is Vitaceae ampelopsis A.humulifoliavar. Heterophylla
ampelopsishumulifoliaBungevar.heterophylla(Thunb.) K.Koch. [A.heterophylla(Thunb.) Sieb.etZucc]root bark.
Herba panici repentics is grass Herba panici repentics
panicumrepensL.herb.
The object of the invention is by realize with under type:
Medicine is made up of the raw material of following weight portion: purple Pueraria lobota 1 ~ 2 weight portion, Herba panici repentics 1 ~ 2 weight portion.
This medicine is preferably made up of the raw material of following weight portion: purple Pueraria lobota 1 weight portion, Herba panici repentics 2 weight portion.
This medicine is preferably made up of the raw material of following weight portion: purple Pueraria lobota 2 weight portion, Herba panici repentics 1 weight portion.
This medicine is preferably made up of the raw material of following weight portion: purple Pueraria lobota 1 weight portion, Herba panici repentics 1 weight portion.
Tablet, pill, powder, hard capsule, soft capsule, granule can be prepared in described medicine.
Described medicine is adopted and is prepared with the following method: get purple Pueraria lobota, Herba panici repentics, and mixing adds the water soaking 0.5 ~ 2 hour of 3 ~ 15 times amount, decoct 0.5 ~ 2 hour, decoct 2 ~ 4 times, each 0.5 ~ 2 hour, extracting solution merges, and filters, and filtrate concentrates, dry, be ground into fine powder, add adjuvant, mixing, make powder, to obtain final product.
Described medicine is adopted and is prepared with the following method: get dry purple Pueraria lobota, Herba panici repentics, and first time adds 11 times amount water soaking 1 hour, decocts 1 hour, and second time adds 4 times amount soak by water 1 hour, merges decocting liquid, filter, filtrate concentrates, and dry, pulverize into fine powder, sieve, mixing, makes powder, to obtain final product.
Described medicine is adopted and is detected with the following method: adopt high performance liquid chromatography to carry out the assay of salicin:
(1) chromatographic condition: adopt HypersilDs chromatographic column; Mobile phase: ratio is methanol-0.15% phosphoric acid solution of 20 ~ 40:60 ~ 80; Determined wavelength: 190 ~ 210nm; Column temperature: 15 ~ 25 DEG C; Flow velocity: 0.5 ~ 1.5mLmin
-1; Sample size: 5 ~ 20 μ L;
(2) reference substance solution preparation: it is appropriate that precision takes the salicin comparison product being dried to constant weight, adds dissolve with methanol and make reference substance solution;
(3) preparation of need testing solution: precision takes medicine of the present invention, adds methanol, reflux, extracting solution reflux solvent is also concentrated into dry, and residue is dissolved in water, and extracts with water saturated n-butyl alcohol jolting, merge n-butanol extracting liquid, with ammonia solution washing, n-butanol extracting liquid recycling design is to dry, and residue adds dissolve with methanol, shake up, filter, get filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, each 5 ~ 20 μ L of reference substance solution respectively, inject high performance liquid chromatograph, detect.
Described medicine is preferably adopted and is detected with the following method: adopt high performance liquid chromatography to carry out the assay of salicin:
(1) chromatographic condition: adopt HypersilDs chromatographic column; Mobile phase: ratio is methanol-0.15% phosphoric acid solution of 30:70; Determined wavelength: 200nm; Column temperature: 20 DEG C; Flow velocity: 1.0mLmin
-1; Sample size: 10 μ L;
(2) reference substance solution preparation: it is appropriate that precision takes 80 DEG C of salicin comparison product being dried to constant weight, adds dissolve with methanol and makes the reference substance solution of every 1mL containing 0.2mg;
(3) preparation of need testing solution: precision takes medicine 10g of the present invention, adds methanol 40mL, reflux 4h, extracting solution reflux solvent is also concentrated into dry, residue add water 10mL dissolve, extract 5 times with water saturated n-butyl alcohol jolting, each 20mL, merges n-butanol extracting liquid, washs 3 times with ammonia solution, each 15mL, n-butanol extracting liquid recycling design is to dry, and residue adds dissolve with methanol and is transferred in 10mL volumetric flask, add methanol to scale, shake up, filter, get filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, each 10 μ L of reference substance solution respectively, inject high performance liquid chromatograph, detect.
Described medicine can be used for preparing treatment mammitis of cow, the medicine of cattle acute enteritis or health product.
experiment one: the experimental study of Drug therapy mammitis of cow of the present invention
1 experiment material
1.1 test drug
medicine of the present invention
Prescription: purple Pueraria lobota 50g, Herba panici repentics 50g
Preparation method: get dry purple Pueraria lobota 50g, Herba panici repentics 50g and add 1100mL water soaking 1 hour for the first time, decoct 1 hour, second time adds 400mL, decocts 1 hour, merges decocting liquid, filters, and filtrate concentrates, and drying, obtains medicine of the present invention.
drugs compared A
Prescription: purple Pueraria lobota 100g
Preparation method: get dry purple Pueraria lobota 100g, first time adds 1100mL water soaking 1 hour, decocts 1 hour, and second time adds 400mL, decocts 1 hour, merges decocting liquid, filters, and filtrate concentrates, dry, obtains drugs compared A.
drugs compared B
Prescription: Herba panici repentics 100g
Preparation method: get dry Herba panici repentics 100g, first time adds 1100mL water soaking 1 hour, decocts 1 hour, and second time adds 400mL, decocts 1 hour, merges decocting liquid, filters, and filtrate concentrates, dry, obtains drugs compared B.
1.2 experimental animal
400, cattle farm, The Cloud Terrace farm, Lianyungang lactating cow, California mastitis detection method (CMT) detection is carried out to the milch cow that milk yield declines, choose the positive milch cow of more than 90 " ++ ", be divided into three groups at random, i.e. medication therapy groups of the present invention, drugs compared A treatment group, drugs compared B treatment group, often organizes 30.
1.3 test equipment
Bao Dinglan, Baoding rope, dispensing bottle, 50mL syringe, No. 20 lactogenesis pins, California mastitis detection method (CMT) inspection panels.
2 test methods
2.1 California mastitis detection methods
The CMT diagnosticum of the milk and dilution of drawing Isodose respectively adds inspection panel, fully mixes, observes.California mastitis detection method criterion is as described in test kit description, and mammitis of cow therapeutic effect criterion is in table 1.
Table 1 mammitis of cow therapeutic effect criterion
2.2 clinical grouping administrations
Medication therapy groups of the present invention: medicine 10g of the present invention, soak with boiled water, stir after cooling, gavage with dispensing bottle, each 100mL, 1 time/d, being used in conjunction 5d is a course for the treatment of.
Drugs compared A treatment group: drugs compared A10g, soak with boiled water, stir after cooling, gavage with dispensing bottle, each 100mL, 1 time/d, being used in conjunction 5d is a course for the treatment of.
Drugs compared B group: drugs compared B10g, soak with boiled water, stir after cooling, gavage with dispensing bottle, each 100mL, 1 time/d, being used in conjunction 5d is a course for the treatment of.
For test milch cow, carry out unified feeding and management, unified feed formula, different pharmaceutical treats three courses for the treatment of, amounts to 15d.After three courses for the treatment of, CMT detection is carried out to three groups of milch cows.
3 results
The positive milch cow of 3.1 mastitiss
Application California mastitis detection method detects 400 cows in milk, the positive milch cow more than " ++ " 150, and positive rate reaches 37.5%, wherein has 100 of red, swollen, hot, symptom bitterly, accounts for choose 90 in positive milch cow 66.7%, 100 and do clinical trial.
3.2 different pharmaceutical therapeutic effect
After three courses for the treatment of, CMT detection is carried out to the therapeutic effect of three groups of milch cows, and whether recur in reinspection in the 20th day, the results are shown in Table 2.The cure rate of medicine group of the present invention, drugs compared A group and drugs compared B group mammitis of cow is 58.6%, 38.2%, 41.1% respectively, and effective percentage is 90.2%, 74.1%, 85.5% respectively, and relapse rate is 3.6%, 12.8%, 11.92% respectively;
Table 2 three groups of different pharmaceutical therapeutic effect comparative test result
4 conclusions
Result of the test shows, the cure rate of medicine group of the present invention, drugs compared A group and drugs compared B group, effective percentage, relapse rate significant difference (P<0.05).In cure rate, medicine group of the present invention is not higher 20.4 percentage points and 17.4 percentage points than drugs compared A group, drugs compared B component; In effective percentage, medicine group of the present invention is not higher 16.1 percentage points and 4.7 percentage points than drugs compared A group, drugs compared B component, and the therapeutic effect of this sufficient proof medicine of the present invention is better than drugs compared A and drugs compared B.Illustrate that the compatibility in medicine of the present invention between two kinds of flavour of a drug is superior, indispensable, the combination between two kinds of flavour of a drug creates obvious synergistic function, creates the technique effect that one-plus-one is greater than two.In addition, finding in this test that the mastitis of 33.3% suffers from cattle is inapparent infection, and do not show obvious clinical inflammatory pathological changes, suggestion plant pays much attention to the harm of latent mammitis.
experiment two: the quality determining method research of medicine of the present invention
1 instrument and reagent
1.1 instrument
High performance liquid chromatograph (Agilent110 high performance liquid chromatograph and work station, G1311Aquat pump, G1314 UV-detector).
1.2 reagent
Salicin (salicin) reference substance (Chinese pharmaceutical biological product calibrating academy); Chinese medicine composition of the present invention; Chinese crude drug (Kang Ji chain pharmacy provides); Methanol (chromatograph alcohol, biochemical work auxiliary reagent factory, Shanghai); Other reagent are analytical pure.
2 methods and result
2.1 prescription
Purple Pueraria lobota 500g, Herba panici repentics 500g.
2.2 preparation
Get dry purple Pueraria lobota 500g, Herba panici repentics 500g, first time adds 11000mL water soaking 1 hour, decocts 1 hour, and second time adds 4000mL, decocts 1 hour, merges decocting liquid, filters, and filtrate concentrates, dry, to obtain final product.
The assay of 2.3 salicins
2.3.1HPLC chromatographic condition
Adopt HypersilDs(4.0mm × 125mm, 5 μm) chromatographic column; Mobile phase: ratio is methanol-0.15% phosphoric acid solution of 30:70; Determined wavelength: 200nm; Column temperature: 20 DEG C; Flow velocity: 1.0mLmin
-1; Sample size: 10 μ L; Under this chromatographic condition, reference substance and sample chromatogram peak are well, noiseless to mensuration without Herba panici repentics negative control.
2.3.2 the preparation of reference substance solution
It is appropriate that precision takes 80 DEG C of salicin comparison product being dried to constant weight, adds methanol and make the solution of every 1mL containing 0.2mg.
2.3.3 the preparation of need testing solution and negative controls
Precision takes medicine 10g of the present invention, adds methanol 40mL, reflux 4h, extracting solution reflux solvent is also concentrated into dry, residue add water 10mL dissolve, extract 5 times with water saturated n-butyl alcohol jolting, each 20mL, merges n-butanol extracting liquid, washs 3 times with ammonia solution, each 15mL, n-butanol extracting liquid recycling design is to dry, and residue adds dissolve with methanol and is transferred in 10mL volumetric flask, add methanol to scale, shake up, filter, get filtrate and get final product; Separately do not contain the negative controls of Herba panici repentics in the preparation of prescription ratio, be made in the same way of negative controls.
2.3.4 the drafting of standard curve
It is appropriate that precision takes 80 DEG C of salicin comparison product being dried to constant weight, makes 10.4,20.8,41.6,83.2,166.4 μ gmL with methanol
-1the solution of series concentration, precision measures each 10 μ L of above-mentioned 5 kinds of strength solution respectively, injects high performance liquid chromatograph and measures.
Carry out linear regression with peak area ratio and concentration, obtaining regression equation is: A=21.2763C-0.1391, r=0.9999.Show that salicin is at 10.4 ~ 166.4 μ gmL
-1in good linear relationship in concentration range.
2.3.5 stability test
Accurate absorption need testing solution 10 μ L, respectively at 0,1,2,4,8h sample introduction, and calculates salicin content.In result 8h, RSD is 0.45%(n=5).Show that sample solution is stable in 8h.
2.3.6 replica test
By 5 parts, need testing solution preparation method parallel processing sample, measure salicin content in accordance with the law and calculate.It is 0.12mgg that result records salicin average content
-1, RSD is 1.3%.
2.3.7 Precision Experiment
Accurate absorption salicin comparison product solution, repeats sample introduction 5 times, measures peak area in accordance with the law.Result RSD is 0.23%(n=5).Show that precision is better.
2.3.8 response rate experiment
Precision takes 6 parts, the sample of the same lot number of known water benzasalicin content, adds appropriate salicin comparison product solution, operate, measure in accordance with the law, calculate the response rate by under sample determination item by high, medium and low concentration is accurate respectively.Result average recovery rate is 100.3%, RSD is 0.45%(n=5).
2.3.9 sample size measures
Measure reference substance solution and need testing solution respectively appropriate, filter with microporous filter membrane, each sample introduction 10 μ L, measures 3 batch samples by above-mentioned chromatographic condition, parallel assay 5 times.By external standard method with the content of calculated by peak area need testing solution salicin.This product should be containing salicin and indicates 95% ~ 105% of content, in every 1g sample containing salicin, must not be less than 0.12mg.3 batch sample content are respectively 100.8%(RSD=1.2%), 101.7%(RSD=1.3%), 99.2%(RSD=1.1%).
detailed description of the invention:
Embodiment 1, a kind of medicine for the treatment of mammitis of cow, this medicine is made up of the raw material of following weight portion: purple Pueraria lobota 1 weight portion, Herba panici repentics 2 weight portion.
Embodiment 2, a kind of medicine for the treatment of mammitis of cow, this medicine is made up of the raw material of following weight portion: purple Pueraria lobota 2 weight portion, Herba panici repentics 1 weight portion.
Embodiment 3, a kind of medicine for the treatment of mammitis of cow, this medicine is made up of the raw material of following weight portion: purple Pueraria lobota 1.5 weight portion, Herba panici repentics 1 weight portion.
Embodiment 4, a kind of medicine for the treatment of mammitis of cow, this medicine is made up of the raw material of following weight portion: purple Pueraria lobota 1 weight portion, Herba panici repentics 1 weight portion.
Medicine in embodiment 1 ~ 4 described in any one, can by this medicine routinely method for making be prepared into tablet, pill, powder, hard capsule, soft capsule, granule.
Embodiment 5, the medicine in embodiment 1 ~ 4 described in any one, this medicine is adopted and is prepared with the following method: get purple Pueraria lobota, Herba panici repentics, mixing, adds the water soaking 0.5 ~ 2 hour of 3 ~ 15 times amount, decocts 0.5 ~ 2 hour, decoct 2 ~ 4 times, each 0.5 ~ 2 hour, extracting solution merges, filter, filtrate concentrates, dry, be ground into fine powder, add adjuvant, mixing, make powder, to obtain final product.
Embodiment 6, the medicine in embodiment 1 ~ 4 described in any one, this medicine is adopted and is prepared with the following method: get dry purple Pueraria lobota, Herba panici repentics, first time adds 11 times amount water soaking 1 hour, decocts 1 hour, and second time adds 4 times amount soak by water 1 hour, merge decocting liquid, filter, filtrate concentrates, dry, be ground into fine powder, sieve, mixing, make powder, to obtain final product.
Embodiment 7, the medicine in embodiment 5 or 6 described in any one, this medicine adopts high performance liquid chromatography to carry out the assay of salicin:
(1) chromatographic condition: adopt HypersilDs chromatographic column; Mobile phase: ratio is methanol-0.15% phosphoric acid solution of 20 ~ 40:60 ~ 80; Determined wavelength: 190 ~ 210nm; Column temperature: 15 ~ 25 DEG C; Flow velocity: 0.5 ~ 1.5mLmin
-1; Sample size: 5 ~ 20 μ L;
(2) reference substance solution preparation: it is appropriate that precision takes the salicin comparison product being dried to constant weight, adds dissolve with methanol and make reference substance solution;
(3) preparation of need testing solution: precision takes medicine of the present invention, adds methanol, reflux, extracting solution reflux solvent is also concentrated into dry, and residue is dissolved in water, and extracts with water saturated n-butyl alcohol jolting, merge n-butanol extracting liquid, with ammonia solution washing, n-butanol extracting liquid recycling design is to dry, and residue adds dissolve with methanol, shake up, filter, get filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, each 5 ~ 20 μ L of reference substance solution respectively, inject high performance liquid chromatograph, detect.
Embodiment 8, the medicine in embodiment 5 or 6 described in any one, adopts high performance liquid chromatography to carry out the assay of salicin:
(1) chromatographic condition: adopt HypersilDs chromatographic column; Mobile phase: ratio is methanol-0.15% phosphoric acid solution of 30:70; Determined wavelength: 200nm; Column temperature: 20 DEG C; Flow velocity: 1.0mLmin
-1; Sample size: 10 μ L;
(2) reference substance solution preparation: it is appropriate that precision takes 80 DEG C of salicin comparison product being dried to constant weight, adds dissolve with methanol and makes the reference substance solution of every 1mL containing 0.2mg;
(3) preparation of need testing solution: precision takes medicine 10g of the present invention, adds methanol 40mL, reflux 4h, extracting solution reflux solvent is also concentrated into dry, residue add water 10mL dissolve, extract 5 times with water saturated n-butyl alcohol jolting, each 20mL, merges n-butanol extracting liquid, washs 3 times with ammonia solution, each 15mL, n-butanol extracting liquid recycling design is to dry, and residue adds dissolve with methanol and is transferred in 10mL volumetric flask, add methanol to scale, shake up, filter, get filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, each 10 μ L of reference substance solution respectively, inject high performance liquid chromatograph, detect.
embodiment 9: pharmaceutical hard capsule agent of the present invention
Drug prescription: purple Pueraria lobota 500g, Herba panici repentics 500g
Preparation method: get dry purple Pueraria lobota 500g, Herba panici repentics 500g, first time adds 11000mL water soaking 1 hour, decocts 1 hour, and second time adds 4000mL, decoct 1 hour, merge decocting liquid, filter, filtrate concentrates, dry, be ground into fine powder, add adjuvant, mixing, makes powder, makes 1000g.
High performance liquid chromatography is adopted to carry out assay to salicin (salicin):
(1) chromatographic condition: adopt HypersilDs chromatographic column; Mobile phase: ratio is methanol-0.15% phosphoric acid solution of 30:70; Determined wavelength: 200nm; Column temperature: 20 DEG C; Flow velocity: 1.0mLmin
-1; Sample size: 10 μ L;
(2) reference substance solution preparation: it is appropriate that precision takes 80 DEG C of salicin comparison product being dried to constant weight, adds methanol and makes the solution of every 1mL containing 0.2mg;
(3) preparation of need testing solution: precision takes medicine 10g of the present invention, adds methanol 40mL, reflux 4h, extracting solution reflux solvent is also concentrated into dry, residue add water 10mL dissolve, extract 5 times with water saturated n-butyl alcohol jolting, each 20mL, merges n-butanol extracting liquid, washs 3 times with ammonia solution, each 15mL, n-butanol extracting liquid recycling design is to dry, and residue adds dissolve with methanol and is transferred in 10mL volumetric flask, add methanol to scale, shake up, filter, get filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, each 10 μ L of reference substance solution respectively, inject high performance liquid chromatograph, detect, testing result is the content of salicin is 0.1712mg/g.
In addition, be to be understood that, although this description is described according to embodiment, but not each embodiment only comprises an independently technical scheme, this narrating mode of description is only for clarity sake, those skilled in the art should by description integrally, and the technical scheme in each embodiment also through appropriately combined, can form other embodiments that it will be appreciated by those skilled in the art that.
Claims (10)
1. treat a medicine for mammitis of cow, it is characterized in that, this medicine is made up of the raw material of following weight portion: purple Pueraria lobota 1 ~ 2 weight portion, Herba panici repentics 1 ~ 2 weight portion.
2. medicine as claimed in claim 1, it is characterized in that, this medicine is made up of the raw material of following weight portion: purple Pueraria lobota 1 weight portion, Herba panici repentics 2 weight portion.
3. medicine as claimed in claim 1, it is characterized in that, this medicine is made up of the raw material of following weight portion: purple Pueraria lobota 2 weight portion, Herba panici repentics 1 weight portion.
4. as claim 1 medicine, it is characterized in that, this medicine is made up of the raw material of following weight portion: purple Pueraria lobota 1 weight portion, Herba panici repentics 1 weight portion.
5. as the medicine in Claims 1 to 4 as described in any one, it is characterized in that, this medicine is prepared into tablet, pill, powder, hard capsule, soft capsule, granule.
6. medicine as claimed in claim 5, is characterized in that, this medicine is adopted and prepared with the following method: get purple Pueraria lobota, Herba panici repentics, mixing, adds the water soaking 0.5 ~ 2 hour of 3 ~ 15 times amount, decocts 0.5 ~ 2 hour, decoct 2 ~ 4 times, each 0.5 ~ 2 hour, extracting solution merges, filter, filtrate concentrates, dry, be ground into fine powder, add adjuvant, mixing, make powder, to obtain final product.
7. medicine as claimed in claim 6, is characterized in that, this medicine is adopted and prepared with the following method: get dry purple Pueraria lobota, Herba panici repentics, first time adds 11 times amount water soaking 1 hour, decocts 1 hour, and second time adds 4 times amount soak by water 1 hour, merge decocting liquid, filter, filtrate concentrates, dry, be ground into fine powder, sieve, mixing, make powder, to obtain final product.
8. as the medicine in Claims 1 to 4 as described in any one, it is characterized in that, this medicine is adopted and is detected with the following method: adopt high performance liquid chromatography to carry out the assay of salicin:
(1) chromatographic condition: adopt HypersilDs chromatographic column; Mobile phase: ratio is methanol-0.15% phosphoric acid solution of 20 ~ 40:60 ~ 80; Determined wavelength: 190 ~ 210nm; Column temperature: 15 ~ 25 DEG C; Flow velocity: 0.5 ~ 1.5mLmin
-1; Sample size: 5 ~ 20 μ L;
(2) reference substance solution preparation: it is appropriate that precision takes the salicin comparison product being dried to constant weight, adds dissolve with methanol and make reference substance solution;
(3) preparation of need testing solution: precision takes medicine of the present invention, adds methanol, reflux, extracting solution reflux solvent is also concentrated into dry, and residue is dissolved in water, and extracts with water saturated n-butyl alcohol jolting, merge n-butanol extracting liquid, with ammonia solution washing, n-butanol extracting liquid recycling design is to dry, and residue adds dissolve with methanol, shake up, filter, get filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, each 5 ~ 20 μ L of reference substance solution respectively, inject high performance liquid chromatograph, detect.
9. medicine as claimed in claim 8, is characterized in that, this medicine is adopted and detected with the following method: adopt high performance liquid chromatography to carry out the assay of salicin:
(1) chromatographic condition: adopt HypersilDs chromatographic column; Mobile phase: ratio is methanol-0.15% phosphoric acid solution of 30:70; Determined wavelength: 200nm; Column temperature: 20 DEG C; Flow velocity: 1.0mLmin
-1; Sample size: 10 μ L;
(2) reference substance solution preparation: it is appropriate that precision takes 80 DEG C of salicin comparison product being dried to constant weight, adds dissolve with methanol and makes the reference substance solution of every 1mL containing 0.2mg;
(3) preparation of need testing solution: precision takes medicine 10g of the present invention, adds methanol 40mL, reflux 4h, extracting solution reflux solvent is also concentrated into dry, residue add water 10mL dissolve, extract 5 times with water saturated n-butyl alcohol jolting, each 20mL, merges n-butanol extracting liquid, washs 3 times with ammonia solution, each 15mL, n-butanol extracting liquid recycling design is to dry, and residue adds dissolve with methanol and is transferred in 10mL volumetric flask, add methanol to scale, shake up, filter, get filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, each 10 μ L of reference substance solution respectively, inject high performance liquid chromatograph, detect.
10. as the application of the medicine in Claims 1 to 4 as described in any one in the medicine or health product of preparation treatment cattle acute enteritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510538198.3A CN105169004B (en) | 2015-08-28 | 2015-08-28 | A kind of drug that treating mastitis for milk cows and its preparation method and detection method and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510538198.3A CN105169004B (en) | 2015-08-28 | 2015-08-28 | A kind of drug that treating mastitis for milk cows and its preparation method and detection method and purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105169004A true CN105169004A (en) | 2015-12-23 |
| CN105169004B CN105169004B (en) | 2018-11-27 |
Family
ID=54891753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510538198.3A Active CN105169004B (en) | 2015-08-28 | 2015-08-28 | A kind of drug that treating mastitis for milk cows and its preparation method and detection method and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105169004B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106770742A (en) * | 2016-12-07 | 2017-05-31 | 无锡艾科瑞思产品设计与研究有限公司 | A kind of ceftiofur metabolite detection method and kit |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1237448A (en) * | 1999-06-15 | 1999-12-08 | 李珍蓉 | Method for curing tumor of breast by using Chinese herbal medicines |
-
2015
- 2015-08-28 CN CN201510538198.3A patent/CN105169004B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1237448A (en) * | 1999-06-15 | 1999-12-08 | 李珍蓉 | Method for curing tumor of breast by using Chinese herbal medicines |
Non-Patent Citations (3)
| Title |
|---|
| 武瑞等著: "《奶牛乳房炎综合防治》", 30 May 2011, 中国农业出版社 * |
| 翁长江: "饲用药用植物的开发利用", 《中国草食动物》 * |
| 翁长江主编: "《野生饲用药用植物80例》", 31 August 2011, 中国农业科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106770742A (en) * | 2016-12-07 | 2017-05-31 | 无锡艾科瑞思产品设计与研究有限公司 | A kind of ceftiofur metabolite detection method and kit |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105169004B (en) | 2018-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100453094C (en) | Medicine composition of effective parts for compound Tongmai Chinese medicine oral liquid and its preparing method | |
| CN102274314A (en) | Evergreen coccidian powder and preparation method thereof | |
| CN110755386B (en) | Application of thesium Chinese granules in preparation of medicine for treating hyperpyrexia caused by pathogenic bacteria infection | |
| CN1706397B (en) | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte | |
| CN105169004A (en) | Medicine for treating bovine mastitis and preparation method, detection method and application of medicine | |
| CN102526138B (en) | Composition of active components from fresh purslane for decreasing blood sugar and preparation method | |
| CN105031375A (en) | Medicine for treating cow mastitis and preparation method, detecting method and application of medicine | |
| CN101422529B (en) | Preparation method of traditional Chinese medicine preparation | |
| CN105168612A (en) | Drug for treating piglet diarrhea, as well as preparation method, detection method and application thereof | |
| CN104367633A (en) | Medicine combination with antibacterial and synergically-antibacterial effects, and preparation method and application | |
| CN101422522B (en) | Preparation method of traditional Chinese medicine preparation | |
| CN110279754B (en) | Traditional Chinese medicine granule for treating suppurative dermatosis, preparation method and application thereof | |
| CN1704113A (en) | Chinese traditional medicinal preparation containing red sange root and safflower for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
| CN1823982A (en) | Chinese medicinal preparation for liver soothing and speen fortifying and its manufacturing method | |
| CN103735689B (en) | A kind of natural drug composition is preparing the application in anoxia enduring medicine and health product | |
| CN106074495A (en) | Reduce the preparation method of the catechin nanoparticle of aflatoxin bioavailability | |
| CN103505548B (en) | Traditional Chinese medicine used for treating ulcerative colitis, and preparation method and detection method thereof | |
| CN1264506C (en) | Pharmaceutical combination containing red sage root element and preparation method thereof | |
| CN1233401C (en) | Agastache capsule for restoring healthy energy andits prepn and application | |
| CN107281354B (en) | Natural pharmaceutical composition for treating clinical cow mastitis and preparation method thereof | |
| CN1457780A (en) | Total alkaloid composition from plant and its pharmaceutical preparation | |
| CN105125639A (en) | Traditional Chinese medicine composition for preventing and treating mastitis of dairy cattle | |
| CN105380985B (en) | Pharmaceutical composition for treating cerebral arterial thrombosis | |
| CN104825784B (en) | A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application | |
| CN103263467A (en) | Potent medicament of brain-and-heart, preparation method and content determination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |